Literature DB >> 17169128

Long-term survival in patients treated with cardiac resynchronization therapy: a 3-year follow-up study from the InSync/InSync ICD Italian Registry.

Maurizio Gasparini1, Maurizio Lunati, Massimo Santini, Massimo Tritto, Antonio Curnis, Mario Bocchiardo, Antonio Vincenti, Gianfranco Pistis, Sergio Valsecchi, Alessandra Denaro.   

Abstract

BACKGROUND: Studies reporting the long-term survival of patients treated with cardiac resynchronization therapy (CRT) outside the realm of randomized controlled trials are still lacking. The aim of this study was to quantify the survival of patients treated with CRT in clinical practice and to investigate the long-term effects of CRT on clinical status and echocardiographic parameters.
METHODS: The study population consisted of 317 consecutive patients with implanted CRT devices from eight Italian University/Teaching Hospitals. The patients were enrolled in a national observational registry and had a minimum follow-up of 2 years. A visit was performed in surviving patients and mortality data were obtained by hospital file review or direct telephone contact.
RESULTS: During the study period, 83 (26%) patients died. The rate of all-cause mortality was significantly higher in ischemic than nonischemic patients (14% vs 8%, P = 0.002). Multivariate analysis showed that ischemic etiology (HR 1.72, CI 1.06-2.79; P = 0.028) and New York Heart Association (NYHA) class IV (HR 2.87, CI 1.24-6.64; P = 0.014) were the strongest predictors of all-cause mortality. The effects of CRT persisted at long-term follow-up (for at least 2 years) in terms of NYHA class improvement, increase of left ventricular ejection fraction, decrease of QRS duration (all P = 0.0001), and reduction of left ventricular end-diastolic and end-systolic diameters (P = 0.024 and P = 0.011, respectively).
CONCLUSIONS: During long-term (3 years) follow-up after CRT, total mortality rate was 10%/year. The outcome of ischemic patients was worse mainly due to a higher rate of death from progressive heart failure. Ischemic etiology along with NYHA class IV was identified as predictors of death. Benefits of CRT in terms of clinical function and echocardiographic parameters persisted at the time of long-term follow-up.

Entities:  

Mesh:

Year:  2006        PMID: 17169128     DOI: 10.1111/j.1540-8159.2006.00485.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

Review 1.  What can post market registries tell us about the use of cardiac resynchronization therapy?

Authors:  Howard J Eisen
Journal:  Curr Heart Fail Rep       Date:  2007-03

2.  Cardiac resynchronisation therapy: results from daily practice in Rijnstate Hospital, Arnhem.

Authors:  A M Rolink; F W A Verheugt; H A Bosker
Journal:  Neth Heart J       Date:  2009-01       Impact factor: 2.380

3.  Mid-term outcomes in patients implanted with cardiac resynchronization therapy.

Authors:  Sung Ho Lee; Seung-Jung Park; June Soo Kim; Dae-Hee Shin; Dae Kyoung Cho; Young Keun On
Journal:  J Korean Med Sci       Date:  2014-11-21       Impact factor: 2.153

4.  The future of telemedicine for the management of heart failure patients: a Consensus Document of the Italian Association of Hospital Cardiologists (A.N.M.C.O), the Italian Society of Cardiology (S.I.C.) and the Italian Society for Telemedicine and eHealth (Digital S.I.T.).

Authors:  Andrea Di Lenarda; Giancarlo Casolo; Michele Massimo Gulizia; Nadia Aspromonte; Simonetta Scalvini; Andrea Mortara; Gianfranco Alunni; Renato Pietro Ricci; Roberto Mantovan; Giancarmine Russo; Gian Franco Gensini; Francesco Romeo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 5.  What is treatment success in cardiac resynchronization therapy?

Authors:  Paul W X Foley; Francisco Leyva; Michael P Frenneaux
Journal:  Europace       Date:  2009-11       Impact factor: 5.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.